Liquid biopsies are increasingly used for cancer molecular profiling that enables a precision
oncology approach. Circulating extracellular nucleic acids (cell-free DNA; cfDNA) …

In recent years, exceptional technological advances have enabled the identification and
interrogation of rare circulating tumour cells (CTCs) from blood samples of patients, leading …

Over the past 10 years, circulating tumor cells (CTC) and circulating tumor DNA (ctDNA)
have received enormous attention as new biomarkers and subjects of translational research …

Historically, studies of disseminated tumour cells in bone marrow and circulating tumour
cells in peripheral blood have provided crucial insights into cancer biology and the …

Circulating tumor cells (CTCs) are tumor cells that shed from the primary tumor and
intravasate into the peripheral blood circulation system responsible for metastasis. Sensitive …

Liquid biopsy in cancer has gained momentum in clinical research and is experiencing a
boom for a variety of applications. There are significant efforts to utilize liquid biopsies in …

Liquid biopsy has been introduced as a new diagnostic concept predicated on the analysis
of circulating tumour cells (CTCs) or circulating tumour-derived factors, in particular, cell-free …

Precision oncology seeks to leverage molecular information about cancer to improve patient
outcomes. Tissue biopsy samples are widely used to characterize tumours but are limited by …

Importance A significant proportion of patients with early-stage triple-negative breast cancer
(TNBC) are treated with neoadjuvant chemotherapy. Sequencing of circulating tumor DNA …

Metastasis is the major cause of cancer-related deaths; therefore, the prevention and
treatment of metastasis are fundamental to improving clinical outcomes. Epithelial …